- Home
- PTCT
as 08-01-2025 4:00pm EST
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Upcoming Earnings Alert:
Get ready for potential market movements as PTC Therapeutics Inc. PTCT prepares to release earnings report on 07 Aug 2025.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 3.9B | IPO Year: | 2013 |
| Target Price: | $67.64 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.02 - $58.38 | Next Earning Date: | 08-07-2025 |
| Revenue: | $1,772,758,000 | Revenue Growth: | 91.12% |
| Revenue Growth (this year): | 120.38% | Revenue Growth (next year): | -50.29% |
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | May 15 '25 | Sell | $46.10 | 2,812 | $129,716.88 | 103,901 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
PTC Therapeutics Says European Commission Grants it Marketing Authorization for Sephience
PR Newswire
a month ago
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Insider Monkey
a month ago
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches
PR Newswire
a month ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
2 months ago
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
MT Newswires
2 months ago
RBC Raises Price Target on PTC Therapeutics to $60 From $58, Keeps Outperform Rating
Yahoo Finance
2 months ago
This week in Trumponomics: Too bad TACO isn’t true
The Guardian
2 months ago
Starmer says Farage would spook the City and give us Truss 2 – he could be right
Compare PTCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.